PKM2 is a Potential Prognostic Biomarker and Related to Immune Infiltration in Lung Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2023 Dec 14

PMID 38097666

Authors

Lan Yin

Jiaying Shi

Jingfei Zhang

Xinyu Lin

Wenhao Jiang

Yingchuan Zhu

Yue Song

Yilu Lu

Yongxin Ma

Affiliations

Soon will be listed here.

Abstract

Pyruvate kinase M2 (PKM2), a subtype of pyruvate kinase, plays a crucial role as a key enzyme in the final step of glycolysis. It is involved in regulating the tumor microenvironment and accelerating tumor progression. However, the relationship between PKM2 expression and the prognosis and immune infiltration remains unclear in lung cancer. In this study, we analyzed PKM2 expression in pan-cancer, and investigated its association with prognosis and immune cell infiltration of lung cancer by using multiple online databases, including Gent2, Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), PrognoScan, Kaplan-Meier plotter, and The Human Protein Atlas (HPA). The results showed that PKM2 expression is elevated in tumor tissues compared with the adjacent normal tissues of most cancers, including lung cancer. Prognostic analysis indicated that high expression of PKM2 was associated with poorer prognosis in overall lung cancer patients, especially in lung adenocarcinoma (LUAD). Notably, PKM2 exhibited a strong correlation with B cells and CD4+ T cells in LUAD; and with B cells, CD8+ T cells, CD4+ cells, and macrophages in lung squamous cell carcinoma (LUSC). Furthermore, PKM2 expression displayed a significant negative correlation with the expression of immune cell markers in both LUAD and LUSC. These findings suggested that PKM2 could serve as a promising prognostic biomarker for lung cancer and provided insights into its essential role in modulating the immune cell infiltration.

Citing Articles

Effects of macrophages in OSCC progression.

Dong X, Dong C, Li B Front Immunol. 2025; 15:1517886.

PMID: 39877372 PMC: 11772471. DOI: 10.3389/fimmu.2024.1517886.

Prognostic and Therapeutic Implications of Cell Division Cycle 20 Homolog in Breast Cancer.

Messeha S, Zarmouh N, Maku H, Gendy S, Yedjou C, Elhag R Cancers (Basel). 2024; 16(14.

PMID: 39061186 PMC: 11274456. DOI: 10.3390/cancers16142546.

References

Sinha B, Tokar E, Li J, Bushel P . Gene Expression Profiling Elucidates Cellular Responses to NCX4040 in Human Ovarian Tumor Cells: Implications in the Mechanisms of Action of NCX4040. Cancers (Basel). 2023; 15(1). PMC: 9818835. DOI: 10.3390/cancers15010285. View

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View

Wang C, Yu Q, Song T, Wang Z, Song L, Yang Y . The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing. Signal Transduct Target Ther. 2022; 7(1):289. PMC: 9411197. DOI: 10.1038/s41392-022-01130-8. View

Remark R, Becker C, Gomez J, Damotte D, Dieu-Nosjean M, Sautes-Fridman C . The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med. 2014; 191(4):377-90. PMC: 5447326. DOI: 10.1164/rccm.201409-1671PP. View

Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F . PKM2, function and expression and regulation. Cell Biosci. 2019; 9:52. PMC: 6595688. DOI: 10.1186/s13578-019-0317-8. View

Zhu S, Guo Y, Zhang X, Liu H, Yin M, Chen X . Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Cancer Lett. 2020; 503:240-248. DOI: 10.1016/j.canlet.2020.11.018. View

Wang J, Yang P, Yu T, Gao M, Liu D, Zhang J . Lactylation of PKM2 Suppresses Inflammatory Metabolic Adaptation in Pro-inflammatory Macrophages. Int J Biol Sci. 2022; 18(16):6210-6225. PMC: 9682528. DOI: 10.7150/ijbs.75434. View

Gui D, Lewis C, Vander Heiden M . Allosteric regulation of PKM2 allows cellular adaptation to different physiological states. Sci Signal. 2013; 6(263):pe7. DOI: 10.1126/scisignal.2003925. View

Liu C, Liu C, Fu R . Research progress on the role of PKM2 in the immune response. Front Immunol. 2022; 13:936967. PMC: 9365960. DOI: 10.3389/fimmu.2022.936967. View

10.

Chen M, Liu H, Li Z, Ming A, Chen H . Mechanism of PKM2 affecting cancer immunity and metabolism in Tumor Microenvironment. J Cancer. 2021; 12(12):3566-3574. PMC: 8120184. DOI: 10.7150/jca.54430. View

11.

Xia Q, Jia J, Hu C, Lu J, Li J, Xu H . Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma. Oncogene. 2021; 41(6):865-877. PMC: 8816727. DOI: 10.1038/s41388-021-02133-5. View

12.

Xu C, Liu W, Li L, Wang Y, Yuan Q . Serum tumour M2-pyruvate kinase as a biomarker for diagnosis and prognosis of early-stage non-small cell lung cancer. J Cell Mol Med. 2021; 25(15):7335-7341. PMC: 8335667. DOI: 10.1111/jcmm.16762. View

13.

Gu Y, Li X, Bi Y, Zheng Y, Wang J, Li X . CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging (Albany NY). 2020; 12(1):784-807. PMC: 6977663. DOI: 10.18632/aging.102656. View

14.

Mazurek S . Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2010; 43(7):969-80. DOI: 10.1016/j.biocel.2010.02.005. View

15.

Bluemlein K, Gluckmann M, Gruning N, Feichtinger R, Kruger A, Wamelink M . Pyruvate kinase is a dosage-dependent regulator of cellular amino acid homeostasis. Oncotarget. 2012; 3(11):1356-69. PMC: 3717798. DOI: 10.18632/oncotarget.730. View

16.

Damasceno L, Prado D, Veras F, Fonseca M, Toller-Kawahisa J, Rosa M . PKM2 promotes Th17 cell differentiation and autoimmune inflammation by fine-tuning STAT3 activation. J Exp Med. 2020; 217(10). PMC: 7537396. DOI: 10.1084/jem.20190613. View

17.

Luo W, Hu H, Chang R, Zhong J, Knabel M, OMeally R . Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011; 145(5):732-44. PMC: 3130564. DOI: 10.1016/j.cell.2011.03.054. View

18.

Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W . Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature. 2011; 480(7375):118-22. PMC: 3235705. DOI: 10.1038/nature10598. View

19.

Hu H, Tu W, Chen Y, Zhu M, Jin H, Huang T . The combination of PKM2 overexpression and M2 macrophages infiltration confers a poor prognosis for PDAC patients. J Cancer. 2020; 11(8):2022-2031. PMC: 7052945. DOI: 10.7150/jca.38981. View

20.

Bian Z, Zhang J, Li M, Feng Y, Wang X, Zhang J . LncRNA-FEZF1-AS1 Promotes Tumor Proliferation and Metastasis in Colorectal Cancer by Regulating PKM2 Signaling. Clin Cancer Res. 2018; 24(19):4808-4819. DOI: 10.1158/1078-0432.CCR-17-2967. View